Camlin Fine Sciences Limited has received Indian regulatory approvals for its proposed acquisition of a majority stake in French company Vinpai S.A. The approval, granted on November 18, 2025, comes with an adjusted timeline for the completion of the transaction.

Shareholder Approval and Offer Details

The company announced that shareholders have overwhelmingly approved the transaction, with 99.99% of votes in favor. The acquisition is set to proceed at a price of EUR 3.60 per share.

Revised Timeline

Following the regulatory approval, Camlin Fine Sciences has adjusted its acquisition timeline:

• Allotment of consideration shares is now scheduled by November 30, 2025
• Filing of the simplified tender offer is planned for mid-December 2025

This new schedule represents a shift from the earlier target completion date of September 30, 2025, which was announced in a previous update on June 25, 2025.

Reasons for the Earlier Delay

The initial delay was attributed to documentation requirements for foreign sellers involved in the transaction. Specifically, the foreign national sellers needed to obtain Permanent Account Numbers (PANs), a prerequisite for preferential allotment under Securities and Exchange Board of India (SEBI) regulations.

Progress and Next Steps

With the regulatory approvals now in place and the timeline adjusted, Camlin Fine Sciences is moving forward with the next phases of the acquisition process. The company is likely to proceed with the issuance of equity shares through preferential allotment as payment for acquiring the majority stake in Vinpai via a share swap arrangement.

Background of the Acquisition

The proposed acquisition was initially disclosed on February 24, 2025, when Camlin Fine Sciences executed a Share Purchase Agreement (SPA) with certain significant shareholders of Vinpai, including its founders.

Regulatory Compliance

Camlin Fine Sciences has assured stakeholders that it is adhering to all necessary regulatory requirements. The company has been providing relevant details as mandated under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

As Camlin Fine Sciences progresses with its plans to acquire a majority stake in Vinpai S.A., investors and industry observers will be watching for further developments in this strategic move. The successful navigation of regulatory approvals marks a significant milestone in this cross-border transaction, setting the stage for the final phases of the acquisition process.

Camlin Fine Sciences Limited , a leading manufacturer of specialty chemicals and blends, reported a revenue of Rs. 460.00 crores for the second quarter of fiscal year 2026, marking an 8.6% growth compared to the previous quarter. The company's performance was driven by increased volumes in trades, blends, and vanillin segments, despite facing realization pressures from US tariffs.

Key Highlights

• Revenue reached Rs. 460.00 crores, up 8.6% quarter-on-quarter
• EBITDA improved to Rs. 33.00 crores with a 7.27% margin
• Vanillin sales volume increased by 35% compared to the previous quarter
• Blends business grew by 8% in the quarter

Segment Performance

Vanillin Segment

The company reported a significant 35% increase in vanillin sales volume compared to the previous quarter. However, realizations were under pressure due to the 50% tariff imposed on Indian exports to the US. Camlin Fine Sciences is currently operating its vanillin plant at 50-60% capacity utilization.

Blends Business

The blends segment showed resilience with an 8% growth in the quarter. The company has strengthened its marketing team across regions, including the US, Brazil, Europe, and India, to support future growth in this segment.

Trades and Straights Business

The company experienced volume growth in its trades and straights business, particularly in TBHQ and BHA products. However, the segment faced realization pressure due to increased local competition in India.

Outlook

Camlin Fine Sciences provided guidance for the coming year:

1. Vanillin Sales: The company aims to achieve 4,000 tons of vanillin sales in the next fiscal year.
2. Blends Growth: Management expects the blends business to grow by 20% in the coming year.

Market Challenges and Strategies

The company faces challenges from US tariffs and channel inventory in both US and European markets. Management expects the destocking in the US to be completed by Q4 of this fiscal year and in Europe by Q1 of FY27.

To address these challenges and drive growth, Camlin Fine Sciences is:

1. Expanding its sales force, having added 31 new employees in the last quarter
2. Pursuing inorganic growth opportunities, with an acquisition in France expected to be completed soon
3. Focusing on optimizing capacity utilization to improve cost efficiency

Management Commentary

Nirmal Momaya, Managing Director, stated, "We are on track for the growth which we have been projecting in blends. For vanillin, we are good for the 2,500 tons target this year, and for blends, we are okay with the 18-20% growth we've been projecting."

Camlin Fine Sciences remains cautiously optimistic about its future prospects, balancing the challenges posed by global trade dynamics with strategic initiatives to drive growth across its key business segments.